The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer
Investigative and Clinical Urology · 2025
DOI: 10.4111/icu.20250111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative and Clinical Urology, 2025. Verfasst von Hyomyoung Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Seoul National University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Adjuvants, Immunologic, Cystectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SNU, Korea Health Industry Development Institute, Seoul National University.
Abstract (Originalsprache)
PURPOSE: This study aimed to evaluate whether the pathological findings from repeat transurethral resection of bladder (re-TURB) predict Bacillus Calmette-Guérin (BCG) response in patients with T1 high-grade bladder cancer. MATERIALS AND METHODS: We analyzed patients with bladder cancer enrolled in the prospective patient registry system of Seoul National University, SUPER-UC, from March 2016 to May 2022. Patients with T1 high-grade cancer who underwent re-TURB and BCG instillation were identified. Re-TURB pathology and its relationship with BCG response were analyzed. RESULTS: Out of a total of 2,673 patients with bladder cancer, 539 had T1 high-grade bladder cancer. Among these, 251 patients underwent subsequent re-TURB and BCG instillation. Of the 251 patients, 210 (83.7%) were male, and TURB was performed as the initial procedure in 232 cases (92.4%). In the TURB specimens of T1 high-grade cancer, concomitant carcinoma in situ (CIS), lymphovascular invasion, and variant histology were observed in 27 (10.8%), 54 (21.5%), and 29 (11.6%) cases, respectively. However, these factors were not associated with BCG failure after re-TURB. Re-TURB pathology showed chronic inflammation (51.8%), CIS (17.5%), Ta (15.5%), and T1 (15.1%). These findings were significantly correlated with BCG responsiveness. Notably, BCG failure was reported in 20.8% of patients with chronic inflammation, which showed the best response, compared to patients with T1 pathology, where BCG failure was observed in 47.4% of cases (p=0.011). CONCLUSIONS: The pathological results of re-TURB play a critical role in determining the BCG response in patients with T1 high-grade bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Seoul National University Hospital, Seoul, Korea.
- Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Urology, Seoul National University College of Medicine, Seoul, Korea. 11shjeong@snu.ac.kr.
ORCID-Profile: Hyomyoung Lee, Sang Won So, Jang Hee Han, Hyeong Dong Yuk, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Seung-Hwan Jeong
Förderung
- SNU
- Korea Health Industry Development Institute
- Seoul National University
Zitieren
APA
Lee, H., So, S. W., Han, J. H., Yuk, H. D., Jeong, C. W., Ku, J. H., Kwak, C., & Jeong, S. H. (2025). The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer. Investigative and Clinical Urology. https://doi.org/10.4111/icu.20250111
Vancouver
Lee H, So SW, Han JH, Yuk HD, Jeong CW, Ku JH, et al. The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer. Investigative and Clinical Urology. 2025. doi:10.4111/icu.20250111
BibTeX
@article{Lee2025,
author = {Lee, Hyomyoung and So, Sang Won and Han, Jang Hee and Yuk, Hyeong Dong and Jeong, Chang Wook and Ku, Ja Hyeon and Kwak, Cheol and Jeong, Seung-Hwan},
title = {The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer},
journal = {Investigative and Clinical Urology},
year = {2025},
doi = {10.4111/icu.20250111}
}
EUVIMED